Cargando…
Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial
BACKGROUND: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40–50 % at 1 year. Previous small studies and observation...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866413/ https://www.ncbi.nlm.nih.gov/pubmed/27175481 http://dx.doi.org/10.1186/s13063-016-1372-7 |
_version_ | 1782431916174082048 |
---|---|
author | Karunanithy, Narayan Mesa, Irene Rebollo Dorling, Anthony Calder, Francis Katsanos, Konstantinos Semik, Vikki Robinson, Emily Peacock, Janet Das, Neelanjan Forman, Colin Lawman, Sarah Steiner, Kate Wilkins, C Jason Robson, Michael G |
author_facet | Karunanithy, Narayan Mesa, Irene Rebollo Dorling, Anthony Calder, Francis Katsanos, Konstantinos Semik, Vikki Robinson, Emily Peacock, Janet Das, Neelanjan Forman, Colin Lawman, Sarah Steiner, Kate Wilkins, C Jason Robson, Michael G |
author_sort | Karunanithy, Narayan |
collection | PubMed |
description | BACKGROUND: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40–50 % at 1 year. Previous small studies and observational data suggest that paclitaxel-coated balloons may be of benefit in improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. METHODS/DESIGN: We have designed a multicentre, double-blind randomised controlled trial to test the superiority of paclitaxel-coated balloons for preventing restenosis after fistuloplasty in patients with a native arteriovenous fistula. Two hundred and eleven patients will be followed up for a minimum of 1 year. Inclusion criteria include a clinical indication for a fistuloplasty, an access circuit that is free of synthetic graft material or stents, and a residual stenosis of 30 % or less after plain balloon fistuloplasty. Exclusion criteria include a synchronous venous lesion in the same access circuit, location of the stenosis central to the thoracic inlet or a thrombosed access circuit at the time of treatment. The primary endpoint is time to end of target lesion primary patency. This is defined as a clinically-driven radiological or surgical re-intervention at the treatment segment, thrombosis that includes the treatment segment, or abandonment of the access circuit due to an inability to re-treat the treatment segment. Secondary endpoints include angiographic late lumen loss, time to end of access circuit cumulative patency, the total number of interventions, and quality of life. The trial is funded by the National Institute for Health Research. DISCUSSION: We anticipate that this trial will provide rigorous data that will determine the efficacy of additional paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis. TRIAL REGISTRATION: ISRCTN14284759. Registered on 28 October 2015. |
format | Online Article Text |
id | pubmed-4866413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48664132016-05-14 Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial Karunanithy, Narayan Mesa, Irene Rebollo Dorling, Anthony Calder, Francis Katsanos, Konstantinos Semik, Vikki Robinson, Emily Peacock, Janet Das, Neelanjan Forman, Colin Lawman, Sarah Steiner, Kate Wilkins, C Jason Robson, Michael G Trials Study Protocol BACKGROUND: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40–50 % at 1 year. Previous small studies and observational data suggest that paclitaxel-coated balloons may be of benefit in improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. METHODS/DESIGN: We have designed a multicentre, double-blind randomised controlled trial to test the superiority of paclitaxel-coated balloons for preventing restenosis after fistuloplasty in patients with a native arteriovenous fistula. Two hundred and eleven patients will be followed up for a minimum of 1 year. Inclusion criteria include a clinical indication for a fistuloplasty, an access circuit that is free of synthetic graft material or stents, and a residual stenosis of 30 % or less after plain balloon fistuloplasty. Exclusion criteria include a synchronous venous lesion in the same access circuit, location of the stenosis central to the thoracic inlet or a thrombosed access circuit at the time of treatment. The primary endpoint is time to end of target lesion primary patency. This is defined as a clinically-driven radiological or surgical re-intervention at the treatment segment, thrombosis that includes the treatment segment, or abandonment of the access circuit due to an inability to re-treat the treatment segment. Secondary endpoints include angiographic late lumen loss, time to end of access circuit cumulative patency, the total number of interventions, and quality of life. The trial is funded by the National Institute for Health Research. DISCUSSION: We anticipate that this trial will provide rigorous data that will determine the efficacy of additional paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis. TRIAL REGISTRATION: ISRCTN14284759. Registered on 28 October 2015. BioMed Central 2016-05-12 /pmc/articles/PMC4866413/ /pubmed/27175481 http://dx.doi.org/10.1186/s13063-016-1372-7 Text en © Karunanithy et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Karunanithy, Narayan Mesa, Irene Rebollo Dorling, Anthony Calder, Francis Katsanos, Konstantinos Semik, Vikki Robinson, Emily Peacock, Janet Das, Neelanjan Forman, Colin Lawman, Sarah Steiner, Kate Wilkins, C Jason Robson, Michael G Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial |
title | Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial |
title_full | Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial |
title_fullStr | Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial |
title_full_unstemmed | Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial |
title_short | Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial |
title_sort | paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (pave): study protocol for a randomised controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866413/ https://www.ncbi.nlm.nih.gov/pubmed/27175481 http://dx.doi.org/10.1186/s13063-016-1372-7 |
work_keys_str_mv | AT karunanithynarayan paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT mesairenerebollo paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT dorlinganthony paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT calderfrancis paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT katsanoskonstantinos paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT semikvikki paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT robinsonemily paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT peacockjanet paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT dasneelanjan paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT formancolin paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT lawmansarah paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT steinerkate paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT wilkinscjason paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial AT robsonmichaelg paclitaxelcoatedballoonfistuloplastyversusplainballoonfistuloplastyonlytopreservethepatencyofarteriovenousfistulaeusedforhaemodialysispavestudyprotocolforarandomisedcontrolledtrial |